Head to Head Comparison: Interpace Biosciences (OTCMKTS:IDXG) & Arch Therapeutics (OTCMKTS:ARTH)

Risk and Volatility

Interpace Biosciences has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Arch Therapeutics has a beta of 4.02, indicating that its stock price is 302% more volatile than the S&P 500.

Profitability

This table compares Interpace Biosciences and Arch Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Interpace Biosciences	63.46%	493.02%	137.46%
Arch Therapeutics	-8,257.70%	N/A	-730.22%

Insider & Institutional Ownership

5.7% of Interpace Biosciences shares are held by institutional investors. Comparatively, 6.9% of Arch Therapeutics shares are held by institutional investors. 5.5% of Interpace Biosciences shares are held by company insiders. Comparatively, 4.5% of Arch Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Interpace Biosciences and Arch Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interpace Biosciences	$38.73 million	0.25	$24.58 million	($0.02)	-110.00
Arch Therapeutics	$80,000.00	0.00	-$6.98 million	($2.34)	N/A

Interpace Biosciences has higher revenue and earnings than Arch Therapeutics. Interpace Biosciences is trading at a lower price-to-earnings ratio than Arch Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Interpace Biosciences beats Arch Therapeutics on 7 of the 9 factors compared between the two stocks.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

About Arch Therapeutics

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.